In summary, our results suggest that breast cancer patients with GSTM1‐present genotype may gain a better survival outcome when comparing to their wild‐type counterparts, but the benefit probably compromises due to the intervention of adjuvant chemotherapy. This evidence concerns the gene GSTM1 and breast carcinoma.